Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Telix Pharmaceuticals Limited

Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix ADSs Commence Trading on Nasdaq
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX TLX
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Files Form 20-F Registration Statement for Nasdaq ADS
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX CAH
‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Reorganisation to Deliver on Strategic Priorities
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Q2 2024 Revenue and Business Highlights, Guidance Upgrade
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Launch of Proposed Initial Public Offering in the United States
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Submits NDA for New Prostate Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Q1 2024 Revenue and Business Update
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.